Drugs & Aging,
Journal Year:
2024,
Volume and Issue:
41(11), P. 881 - 896
Published: Nov. 1, 2024
Obesity
is
a
complex
health
issue
with
growing
prevalence
worldwide.
It
also
becoming
more
prevalent
in
the
population
of
older
adults
(i.e.,
65
years
age
and
older),
affecting
frequency
severity
as
well
other
comorbidities,
quality
life
consequently,
expectancy.
In
this
article
we
review
currently
available
data
on
pharmacotherapy
obesity
its
role
management.
Even
though
there
evidence,
particular
general
population,
favourable
efficacy
safety
profiles
glucagon-like
peptide-1
(GLP-1)
receptor
agonists
liraglutide
semaglutide,
recently
dual
GLP-1
glucose-dependent
insulinotropic
polypeptide
(GIP)
agonist
tirzepatide,
concise
guidelines
for
are
not
to
day.
We
further
discuss
specific
approaches
frequently
represented
phenotype
adults,
sarcopenic
rationale
when
treat
how.
need
drug
trials
focusing
only
weight
loss,
but
geriatric
endpoints
including
muscle
mass
preservation,
bone
fat
distribution
changes
get
enough
evidence-based
recommendation
treatment
sub-population.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(8), P. 4300 - 4300
Published: April 12, 2024
Sarcopenia
is
a
prevalent
degenerative
skeletal
muscle
condition
in
the
elderly
population,
posing
tremendous
burden
on
diseased
individuals
and
healthcare
systems
worldwide.
Conventionally,
sarcopenia
currently
managed
through
nutritional
interventions,
physical
therapy,
lifestyle
modification,
with
no
pharmaceutical
agents
being
approved
for
specific
use
this
disease.
As
pathogenesis
of
still
poorly
understood
there
treatment
recognized
as
universally
effective,
recent
research
efforts
have
been
directed
at
better
comprehending
illness
diversifying
strategies.
In
respect,
paper
overviews
new
advances
correlation
its
underlying
mechanisms.
Specifically,
review
creates
an
updated
framework
sarcopenia,
describing
etiology,
pathogenesis,
risk
factors,
conventional
treatments,
further
discussing
emerging
therapeutic
approaches
like
drug
formulations,
delivery
systems,
stem
cell
therapies,
tissue-engineered
scaffolds
more
detail.
MedComm,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: Jan. 1, 2025
Abstract
Sarcopenia
is
defined
as
a
muscle‐wasting
syndrome
that
occurs
with
accelerated
aging,
while
cachexia
severe
wasting
associated
conditions
such
cancer
and
immunodeficiency
disorders,
which
cannot
be
fully
addressed
through
conventional
nutritional
supplementation.
can
considered
component
of
cachexia,
the
bidirectional
interplay
between
adipose
tissue
skeletal
muscle
potentially
serving
molecular
mechanism
for
both
conditions.
However,
underlying
mechanisms
differ.
Recognizing
distinctions
these
disorders
essential
advancing
basic
translational
research
in
this
area,
enhancing
diagnostic
accuracy
ultimately
achieving
effective
therapeutic
solutions
affected
patients.
This
review
discusses
microenvironment's
changes
contributing
to
conditions,
recent
approaches
like
lifestyle
modifications,
small
molecules,
interventions,
emerging
strategies
gene
editing,
stem
cell
therapy,
gut
microbiome
modulation.
We
also
address
challenges
opportunities
multimodal
aiming
provide
insights
into
pathogenesis
sarcopenia
aiding
innovative
strategy
development
improved
treatments.
Schweizerische medizinische Wochenschrift,
Journal Year:
2025,
Volume and Issue:
155(1), P. 4034 - 4034
Published: Jan. 17, 2025
Sarcopenia
is
a
progressive,
age-related
loss
of
muscle
mass,
strength
and
function.
Given
the
ageing
population
adverse
outcomes
associated
with
sarcopenia,
monitoring
its
epidemiology
particularly
important.
This
study
aimed
to
describe
sarcopenia
prevalence,
5-year
incidence
agreement
between
definitions
using
latest
operational
criteria
in
Swiss
postmenopausal
women.
Postmenopausal
women
from
last
5
years
CoLaus/OsteoLaus
prospective
population-based
cohort
were
included
based
on
complete
case
analysis
(April
2015
October
2022;
Lausanne,
Switzerland).
We
assessed
appendicular
lean
mass
via
Dual
X-ray
Absorptiometry
(GE
Lunar
iDXA),
handgrip
Jamar
Dynamometer
6-metre
gait
speed
at
multiple
visits.
was
defined
and/or
11
definitions,
including
that
European
Working
Group
Older
People
(EWGSOPII,
2019).
Prevalence
measured
as
number
rate
sarcopenic
cases
visit,
while
new
over
2.5
or
years.
A
total
930
included,
mean
(standard
deviation)
age
72.9
(6.9)
years,
BMI
25.7
(4.8)
kg/m2,
16.8
(2.5)
kg,
21.2
(5.5)
1.1
(0.2)
m/s.
prevalence
EWGSOPII
ranged
2.2%
5.7%,
other
varied
0.5%
13.4%.
The
rates
1.9%
4.7%.
increased
significantly
lowest
highest
tertiles
(Fisher's
exact
test,
p
<0.05)
for
most
definitions.
Agreement
predominantly
"none"
"minimal"
according
Cohen
Kappa
score.
highlights
an
increase
beginning
seventh
decade
life,
underscoring
accelerated
decline
health
age.
minimal
need
consensus,
which
would
improve
future
research
clinical
implementations.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(7), P. 3098 - 3098
Published: March 27, 2025
Sarcopenia,
a
serious
consequence
of
chronic
kidney
disease
(CKD),
is
driven
by
elevated
myostatin
(MSTN),
key
inhibitor
muscle
growth.
This
study
explored
the
potential
an
MSTN-specific
antisense
oligonucleotide
(ASO)
in
reversing
CKD-induced
wasting
mouse
model.
Thirty-two
male
C57BL/6J
mice
were
randomly
assigned
to
non-CKD
group
(n
=
8,
regular
diet)
and
CKD
24,
adenine
diet).
was
induced
using
0.2%
adenine-supplemented
diet
for
4
weeks.
Following
this,
sub-grouped
into
(saline,
n
8),
+
Low-Dose
ASO
(25
mg/kg
ASO,
High-Dose
(50
8).
administered
via
subcutaneous
injections
8
Muscle
mass,
treadmill
performance,
grip
strength,
fiber
morphology
assessed
alongside
qPCR
Western
blot
analysis
MSTN,
atrogin-1,
MuRF-1
expression.
therapy
significantly
enhanced
mass
function
enlarged
fibers
while
effectively
downregulating
degradation
markers.
These
improvements
occurred
without
compromising
renal
function,
as
confirmed
BUN,
creatinine,
weight,
histological
analysis.
first
demonstrate
efficacy
mitigating
sarcopenia,
offering
promising
targeted
gene
with
significant
clinical
implications
improving
nutritional
status
physical
performance
CKD.
Clinics and Practice,
Journal Year:
2024,
Volume and Issue:
14(4), P. 1451 - 1467
Published: July 25, 2024
Sarcopenia
is
a
multifactorial
age-related
disorder
that
causes
decrease
in
muscle
mass,
strength,
and
function,
leading
to
alteration
of
movement,
risk
falls,
hospitalization.
This
article
aims
review
recent
findings
on
the
factors
underlying
sarcopenia
strategies
required
delay
counteract
its
symptoms.
We
focus
molecular
linked
ageing,
role
low-grade
chronic
acute
inflammatory
conditions
such
as
cancer,
which
contributes
onset
sarcopenia,
clinical
criteria
for
diagnosis.
The
use
drugs
against
still
subject
debate,
suggested
approaches
restore
health
are
based
adequate
dietary
protein
intake
physical
exercise.
also
highlight
difference
amount
quality
amino
acids
within
animal-
plant-based
diets,
studies
have
often
shown
varying
results
regarding
their
effect
elderly
people.
In
addition,
many
reported
non-pharmacological
approaches,
an
optimization
training
programs
resistance
exercise,
can
be
effective
preventing
delaying
sarcopenia.
These
not
only
improve
maintenance
skeletal
but
reduce
care
costs
life
expectancy
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(19), P. 10766 - 10766
Published: Oct. 7, 2024
Since
sarcopenia
is
a
progressive
condition
that
leads
to
decreased
muscle
mass
and
function,
especially
in
elderly
people,
it
public
health
problem
requires
attention
from
researchers.
This
review
aims
highlight
drug
delivery
systems
have
high
efficient
therapeutic
potential
for
sarcopenia.
Current
as
well
future
research
needs
consider
the
barriers
encountered
realization
of
systems,
such
route
administration,
interaction
with
aggressive
environment
human
body,
loading
agents,
targeted
agents
into
tissue
without
creating
undesirable
adverse
effects.
Thus,
this
paper
sets
framework
existing
possibilities
treatment
sarcopenia,
serving
an
inception
point
interdisciplinary
studies.
